Active ingredients: diclofenac + misoprostol
What it is used for
ARTHROTEC 50 is indicated for patients who require a non-steroidal anti-inflammatory drug (NSAID) together with misoprostol. The diclofenac component of ARTHROTEC 50 is indicated for the treatment of osteoarthritis and rheumatoid arthritis. The misoprostol component of ARTHROTEC 50 is indicated for the prophylaxis of NSAID induced gastric and duodenal ulceration. Known risk factors for NSAID induced gastropathy include age in excess of 60 years, a history of peptic ulcer disease, smoking, previous NSAID gastrointestinal intolerance and the presence of a concomitant disease.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 25 degrees Celsius
- Lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
round, biconvex, white tablets, 10mm diameter, with four As on one side and 'Searle 1411' on the other.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)
Arthrotec 50 (diclofenac sodium/misoprostol) information | myVMC
Arthrotec 50 (diclofenac sodium/misoprostol) is used to relieve a patient of symptoms of osteoarthritis and rheumatoid while protecting their stomach.
Read more on myVMC – Virtual Medical Centre website
Rofecoxib for osteoarthritis | Cochrane
Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information is available at www.vioxx.com.
Read more on Cochrane (Australasian Centre) website